Navigation and Content
You are in  United States of America
or Select a different country

DHL Supply Chain Announces $200 Million Investment in Life Sciences and Healthcare Logistics Expansion


Press Release: Westerville, Ohio, February 13, 2024

DHL Supply Chain, the Americas leader in contract logistics, today announced a $200 million investment dedicated to expanding its life sciences and healthcare capabilities. This strategic move includes the construction of new, state-of-the-art warehouse facilities expanding their footprint to over 13 million square feet. Additionally, the company will invest in cutting-edge warehouse technology to optimize operations and enhance resiliency particularly in the face of unforeseen disruptions.

“Resilient life sciences and healthcare supply chains are critical to the well-being of communities around the world,” said Jim Saponaro, President of Life Sciences and Healthcare, DHL Supply Chain. “This significant investment reflects our commitment to providing the industry with the reliable, efficient, and temperature-controlled logistics solutions that’s needed to deliver life-saving treatments and products to patients in need.”

DHL Supply Chain currently has 35 warehouse facilities dedicated to serving their life sciences customers. With the investment they will grow their network to 40 sites by the end of the year. New warehouses will be built in Pennsylvania and North Carolina, which the company has identified as strategic markets that will help them to better serve the healthcare industry. The new facilities in Pennsylvania will position the company within close proximity to major pharmaceutical hubs and research institutions, enabling faster and more efficient distribution of critical products. Meanwhile the North Carolina facilities will cater to the growing demand for life sciences logistics in the southeast region, offering proximity to major airports and transportation infrastructure.

The company's expansion coincides with an upsurge in the pharmaceutical landscape, characterized by the steady stream of groundbreaking treatments, particularly those targeting weight management and diabetes. This, coupled with the resurgence of domestic drug production, has ignited a demand for enhanced capacity. As brands increasingly ramp up domestic manufacturing, the need for efficient inbound logistics to feed production lines has become integral.

Beyond its physical expansion, DHL Supply Chain is investing in warehouse technologies, including:

  • Automated guided vehicles and autonomous mobile robots: These systems help to boost productivity, address labor challenges and provides flexibility to warehouses especially in picking and material handling.
  • Optimization of network inventory:  Enhanced visibility into inventory deployment levels coupled with dynamic slotting tools enable nimble response to evolving market demands. Customers will also have end-to-end visibility of their inventory using DHL’s MySupplyChain.
  • Temperature-controlled environments: Dedicated cold chain solutions guarantee the integrity of temperature-sensitive products throughout the supply chain.

“Recent events have highlighted the importance of agile and resilient supply chains in the life sciences and healthcare sectors,” said Saponaro. “Our investments in technology and strategic locations will empower our customers to better anticipate and navigate disruptions, ensuring uninterrupted delivery of critical supplies.”

Learn more about DHL Supply Chain’s capabilities across the life sciences and healthcare industry here.